Eli Lilly CEO outlines company priorities

09/25/2008 | Google

Eli Lilly and Co. will focus on developing biotech drugs for personalized treatment and expanding networks with other firms to accelerate drug development as the company faces patent expiration for its best-selling medicines, CEO John Lechleiter said in a speech. Lilly is also planning more job cuts and will not be seeking large-scale mergers or acquisitions, Lechleiter said.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI